Prograf 1mg

Indications for use

Rejection of allograft of liver, kidney or heart (for prevention); rejection of allograft, which is resistant to other modes of immunosuppressive therapy (treatment).

Method of reception and dosage

Prograf should be used under the close supervision of a doctor with the necessary qualifications. Assigns and changes to the immunosuppressive therapy can be done only specialists with experience in the use of the drug in patients with transplanted organs. Parenteral Prograf is prescribed if a patient’s condition does not allow him to take the drug in the form of capsules. Immediately after the improvement (but not longer than 7 days), the patient is transferred to the oral reception of the drug. It should be borne in mind that uncontrolled transfer of patients from one drug of Tacrolimus to another is unsafe (it may cause transplant rejection or increase of the frequency of adverse reactions). Change of the dosage regimen or dosage form is possible only under the supervision of a specialist in the field of transplantology. The transfer should be carried out under careful monitoring of the concentration of Tacrolimus in the blood and with the adjustment of the dose. At the initial stage, patients are usually prescribed a combined use of Prograf with other immunosuppressants. The dose may vary depending on the mode of immunosuppressive therapy. Dose selection is based primarily on a clinical assessment of the risk of rejection and individual tolerance to Prograf, as well as on the monitoring of the concentration of Tacrolimus in the blood. If a patient notices clinical signs of rejection, it is necessary to consider the correction of dosing regimen. The duration of therapy is not limited. Prograf capsules are usually taken orally, with a liquid (preferably water). It is recommended to take a break with a meal (1 hour before or 2 hours after eating). If necessary, the contents of the capsules are mixed with water and injected through a nasogastric probe.

Drug contraindications

Contraindication to the use of Prograf is hypersensitivity to the components of the drug, as well as to other macrolides. Pregnant women are prescribed Prograf only in cases where the expected benefit from its use for a mother is higher than the potential risk for a child. If it is necessary to carry out the treatment during lactation, breastfeeding should be discontinued.